Loading…
← CockpitCompetitor Analysis › 002562.SZ Brother Enterprises Holding Co., Ltd. Class AOpen in the cockpit ↗

Brother Enterprises Holding Co., Ltd. Class A002562.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum weak 32
Mkt cap
$668M
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$7.21M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.2 pp
WACC 6.8%
Hurdle
-9 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥3.95
1D-1.0%
1W-6.2%
1M-12.8%
3M-20.5%
6M-32.8%
YTD-38.9%
1Y-44.5%
ATR %2.9%
52w lowhigh50.8% off high

What Brother Enterprises does

Employees: 2,914

Brother Enterprises at a glance

Size Brother Enterprises (002562.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $668M, the 3002nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.95 on 18 Nov 2026.

Performance Over six months the shares fell 32.8%, against -19.1% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 7.8% over the last twelve months (peer median -4.2%); the operating margin is 4.0% (peer median 9.5%).

Valuation It trades at 1.5× enterprise value to sales against a peer median of 3.0× (3rd cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.2 points below its cost of capital (6.8% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 81002562.SZ 68
Six months, rebased to 100: Brother Enterprises against the median of its 20 peers (local-currency closes).

Brother Enterprises financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.85BCN¥3.61BCN¥3.44BCN¥2.82BCN¥3.41B
Revenue growth—+5%+22%-17%—
Gross profitCN¥894MCN¥542MCN¥464MCN¥253MCN¥810M
EBITDAn/aCN¥550MCN¥440MCN¥187MCN¥699M
Net incomeCN¥109MCN¥95.1MCN¥40.8M-CN¥175MCN¥306M
Free cash flowCN¥67.3M-CN¥66.7M-CN¥102M-CN¥319M-CN¥14.9M
Capital expenditureCN¥59.0MCN¥73.8MCN¥227MCN¥368MCN¥166M
Total debtCN¥1.71BCN¥1.82BCN¥1.99BCN¥1.95BCN¥1.65B

Quarterly statements and history in the cockpit →

Brother Enterprises competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%30015830003960048807753002613007912877301507AVBP0026440024126032620460PHN603669002219317450APN000756002275002562.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Brother Enterprises is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%2.5×5×7.5×30015830003960048807753002613007913015070026440024126032620460PHN603669002219317450APN000756002562.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Brother Enterprises is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300039600488300791301507002644002412603262PHNAPN002275002562.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Brother Enterprises is the large dot.

Brother Enterprises competitors and peer comparison

How Brother Enterprises compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Brother Enterprises against its 20 peers (data as of 18 Nov 2026)
Measure002562.SZPeer medianRank in peer set
1-month return-12.8%-9.3%6th lowest of 21
6-month return-32.8%-19.1%5th lowest of 21
Distance from 52-week high-50.8%-41.8%4th lowest of 21
Revenue growth (TTM)+7.8%-4.2%5th highest of 20
Operating margin4.0%9.5%9th lowest of 21
EV / Sales1.5×3.0×3rd cheapest of 20
Growth the price implies (Req g, 7 yrs)4.0%4.7%6th least demanding of 12
Growth delivered (Del g)+13.5%+7.9%4th highest of 12
Hurdle (Req g minus delivered)-9.5 pp-4.4 pp4th least demanding of 12
ROIC minus cost of capital-0.2 pp+0.4 pp9th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
TSI 603262.SSChina$842M-46%+3%14%4.6×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%2.1×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%5.6×4.7%+18.5%
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%2.9×n/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%4.6×24.6%+38.5%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%0.9×0.5%+7.9%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%2.9×-8.7%+5.5%

Questions

Which companies are Brother Enterprises's closest peers?
The cockpit's peer set: Shanxi Zhendong Pharmaceutical (300158.SZ), Shanghai Kaibao Pharmaceutical (300039.SZ), Tianjin Tianyao Pharmaceuticals (600488.SS), CK Life Sciences International (Holdings) (0775.HK), ABA Chemicals (300261.SZ), Sirio Pharma (300791.SZ), China Shineway Pharmaceutical (2877.HK), Hangzhou Minsheng Healthcare (301507.SZ).
Is Brother Enterprises expensive compared with its peers?
On ev / sales it trades at 1.5× against a peer median of 3.0×, 3rd cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Brother Enterprises stock performed?
Over six months to 18 Nov 2026 the shares returned -32.8% against -19.1% for the median peer; over one year -44.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.